Download SciENCV PDF - UNC Gillings School of Global Public Health

OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
NAME: Lund, Jennifer L.
eRA COMMONS USER NAME (agency login): JENLUND
POSITION TITLE: Assistant Professor
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION
Tufts University, Medford, MA
University of North Carolina at Chapel Hill,
Chapel Hill, NC
University of North Carolina at Chapel Hill,
Chapel Hill, NC
Aarhus University (Denmark), Aarhus
DEGREE
(if applicable)
Completion
Date
MM/YYYY
BA
MSPH
05/2003
12/2009
Economics/International Relations
Epidemiology
PHD
12/2011
Epidemiology
OTH
09/2013
Clinical Epidemiology
FIELD OF STUDY
A. Personal Statement
I am a pharmacoepidemiologist with substantive interests in aging, multimorbidity and oncology and expertise
in health services and comparative effectiveness research. The overall objective of my research is to generate
robust evidence regarding the uses, benefits and harms of medical interventions that will lead to improved
medical decisions, clinical outcomes and quality of life for older cancer patients. My research in geriatric
oncology primarily addresses: 1) the quality of cancer care, 2) the effectiveness and safety of cancer treatment
options and 3) the role of polypharmacy, multimorbidity, and frailty in cancer treatment selection and outcomes.
Through my PhD training, I developed a broad set of analytic tools, including focused training in state-of-the-art
epidemiologic methods and their application to study the utilization and impact of cancer treatments among
older adults. My dissertation work drew upon the Surveillance, Epidemiology and End Results program
(SEER)-Medicare database to examine patterns of chemotherapy uptake and investigate patient, physician,
and hospital factors associated with the dissemination of innovative treatments among older colorectal cancer
patients. I also have international experience using large linked databases in Canada and Denmark. Currently,
I am using SEER-Medicare data to develop my research portfolio in geriatric oncology and have obtained
funding for studies relevant to this application, including: 1) a pilot grant through NC TraCS to develop methods
to improve the measurement of frailty and comorbidity among older cancer patients using administrative data,
2) a PhRMA foundation grant evaluating heterogeneity of the comparative effectiveness of chemotherapy
options among older colon cancer patients and 3) a K12 Paul Calabresi Clinical Oncology Career Development
Award to evaluate polypharmacy, chemotherapy and adverse outcomes among older cancer patients.
1. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying specific
chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013 May;51(5):e27-34.
PubMed PMID: 22080337; PubMed Central PMCID: PMC3290707.
2. Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL. Determinants of adjuvant
oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013 Jun
1;119(11):2038-47. PubMed PMID: 23512326; PubMed Central PMCID: PMC3663924.
3. Lund JL, Frøslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Høyer M. Validity of the Danish
National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. Clin
Epidemiol. 2013;5:327-34. PubMed PMID: 24039450; PubMed Central PMCID: PMC3770491.
B. Positions and Honors
Positions and Employment
2003 - 2004
Associate Analyst, Healthcare Antitrust Practice, National Economic Research Associates,
White Plains, NY
2005 - 2007
Senior Consultant, International Transfer Pricing Economics, Ernst & Young LLP, New York,
NY
2007 - 2009
Research Assistant, Department of Epidemiology, UNC-Chapel Hill , Chapel Hill, NC
2008 - 2008
Summer Fellow, National Cancer Institute, Applied Research Program, Rockville, MD
2009 - 2011
Research Assistant, Worldwide Epidemiology, GlaxoSmithKline , Research Triangle Park, NC
2009 - 2011
Pre-Doctoral Trainee, School of Medicine, Division of Gastroenterology and Hepatology, UNCChapel Hill, Chapel Hill, NC
2010 - 2012
Teaching Assistant, Department of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC
2012 - 2013
Consultant, New England Research Institute, Watertown, MA
2012 - 2013
Consultant, GlaxoSmithKline, Research Triangle Park, NC
2012 - 2013
Post-Doctoral Fellow, Department of Clinical Epidemiology, Aarhus University, Aarhus
2013 Assistant Professor, Department of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC
Other Experience and Professional Memberships
2009 Member, Society of Epidemiological Research (SER)
2009 Member, International Society of Pharmacoepidemiology (ISPE)
2011 Member, American Society of Clinical Oncology (ASCO)
Honors
2003
2003
2008
2010
2011
2011
2012
2013
2015
Graduated summa cum laude, Tufts University
Audrey L. Hale Prize recipient, Tufts University
Methodologies in Healthcare Outcomes in Gastroenterology Trainee Scholarship Recipient,
Gastroenterology Research Group (GRP) and the American Gastroenterological Association
Scholarship Recipient, 26th Annual Meeting for the International Society for
Pharmacoepidemiology
Student Dissertation Workshop Participant, Society for Epidemiologic Research, 3rd Annual
North American Congress of Epidemiology
Student Travel Scholarship Award Recipient, Society for Epidemiologic Research, 3rd Annual
North American Congress of Epidemiology
Delta Omega Honor Society Member, Theta Chapter, UNC-Chapel Hill
Abstract Achievement Award winner, American Society of Hematology
Gordon H. DeFriese Career Development in Aging Research Award, UNC-Chapel Hill
C. Contribution to Science
1. Evaluation of patterns of colorectal cancer treatment. My research seeks to describe patterns of
colorectal cancer (CRC) treatment across a variety of populations in order to evaluate the quality of care
received. CRC mortality has steadily declined over the past decades in the United States, in part due to
advances in treatment. However, the dissemination and uptake of new CRC therapies varies in some
settings according to patients’ age, race/ethnicity, socioeconomic status and level of comorbidity. The
“appropriateness” of CRC treatment among older cancer patients is particularly complex due to the high
prevalence of multimorbidity and competing health risks. As the population ages and new therapies are
developed, uncertainties surrounding optimal treatment approaches for older cancer patients will need to
be addressed.
a. Chawla N, Butler EN, Lund J, Warren JL, Harlan LC, Yabroff KR. Patterns of colorectal cancer care in
Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr. 2013;2013(46):36-61. PubMed PMID:
23962509; PubMed Central PMCID: PMC3888187.
b. Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, Yabroff KR. Patterns of colorectal cancer care in
the United States and Canada: a systematic review. J Natl Cancer Inst Monogr. 2013;2013(46):13-35.
PubMed PMID: 23962508; PubMed Central PMCID: PMC3859290.
c. Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL. Determinants of adjuvant
oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013 Jun
1;119(11):2038-47. PubMed PMID: 23512326; PubMed Central PMCID: PMC3663924.
d. Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the
United States: 1990-2010. Journal of the National Cancer Institute. Forthcoming;
2. Validation of cancer treatments identified using administrative claims and cancer registry data. My
research also assesses the validity of large administrative and cancer registry data for identifying cancer
treatments, including surgery, radiation therapy, hormone therapy and chemotherapy across a variety of
cancer sites. In the era of “big data,” these resources (and others, including electronics medical records)
are increasingly being used to evaluate the dissemination, benefits and harms of cancer treatments in “real
world” settings. However, misclassification of cancer treatments could bias estimates of frequency and
association, warranting continued monitoring and validation, particularly as new therapies are introduced to
the market.
a. Lund JL, Frøslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Høyer M. Validity of the Danish
National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. Clin
Epidemiol. 2013;5:327-34. PubMed PMID: 24039450; PubMed Central PMCID: PMC3770491.
b. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying specific
chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013 May;51(5):e27-34.
PubMed PMID: 22080337; PubMed Central PMCID: PMC3290707.
c. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL. Comparison of SEER
Treatment Data with Medicare Claims. Med Care. 2014 Mar 15;PubMed PMID: 24638121.
3. Description of economic burden of cancer. My research also addresses the economic burden of cancer
survivorship. Given the rising price tag of cancer drugs and changes in insurance coverage due to the
Affordable Care Act, the impact of a cancer diagnosis and treatment on patients’ out-of-pocket medical
spending varies widely, but on average is increasing. However, my work with colleagues at the National
Cancer Institute has drawn attention to the fact that the “costs” or economic burden of cancer are not only
those incurred by patients directly through their interaction with the healthcare system (e.g., surgery,
hospitalization, chemotherapy), but encompass a wide range of indirect (e.g., time spent seeking medical
care for patients and caregivers, time lost from work, etc.) and psychosocial (e.g., decreases in quality of
life through feelings of loneliness, anxiety, loss of control, etc.)) costs. This collaborative work highlights the
need for further research into the multidimensional nature of the costs of cancer care and their impact on
the patient experience, which will serve to shape future health care policies to improve the cancer
survivorship experience.
a. Lund JL, Yabroff KR, Ibuka Y, Russell LB, Barnett PG, Lipscomb J, Lawrence WF, Brown ML.
Inventory of data sources for estimating health care costs in the United States. Med Care. 2009
Jul;47(7 Suppl 1):S127-42. PubMed PMID: 19536009; PubMed Central PMCID: PMC3097385.
b. Lund JL, Yabroff KR. Cancer Rehabilitation and Survivorship: A Transdisciplinary Approach. Lester J,
Schmitt P, editors. Pittsburgh, PA: Oncology Nursing Society; 2011. Chapter 23, Economic Burden of
Cancer Survivorship in the United States; p.239-46.
c. Tompa E, Lund JL, Yabroff KR. Health Services for Cancer Survivors: Practice, Policy and Research.
Feuerstein M, Ganz PA, editors. New York, NY: Springer; 2011. Chapter 15, Health Economics and
Cancer Survivorship; p.299-328.
d. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates,
projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14.
PubMed PMID: 21980008; PubMed Central PMCID: PMC3191884.
Complete List of Published Work in My Bibliography:
http://www.ncbi.nlm.nih.gov/myncbi/1zIfcqiKRRckm/bibliography/40957013/public/?sort=date&direction=ascen
ding
D. Research Support
Awarded
NA
PI (Sharpless)
07/01/15-06/30/17
K12 Paul Calabresi Career Development Award for Clinical Oncology – UNC-Chapel Hill
Medication use, chemotherapy and adverse outcomes among older cancer patients
This study will use the SEER-Medicare database to describe the prevalence and outcomes of polypharmacy,
potentially inappropriate medication use and medications with the potential to interact with chemotherapy
among older adults initiating chemotherapy for the treatment of non-metastatic breast, colon and lung cancer
or non-Hodgkin lymphoma.
Ongoing Research Support
NA
PI (Lund)
01/01/15-12/31/15
PhRMA Foundation
Evaluating the heterogeneity of cancer treatment benefits among older adults
The goal of this study is to evaluate whether claims-based measures of multimorbidity and frailty modify the
comparative effectiveness of adjuvant chemotherapy with and without oxaliplatin among older stage III colon
cancer patients using the SEER-Medicare linked data.
Role: PI
550KR61327
PI (Lund, Sanoff)
06/01/14-05/31/15
NC TraCS Pilot Award (1UL1TR001111)
Improved measurement of patient frailty and comorbidity for targeting subgroups of older adults in cancer
comparative effectiveness research
This study will develop and validate claims-based measures of patient frailty and severity of comorbid disease
using two data sources: the SEER-Medicare linked data and the Medicare Current Beneficiary Survey.
Role: Co-PI
Completed Research Support
T32 DK007634-22
PI (Sandler)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Digestive Disease Epidemiology Training Program
Role: TA
07/10/90-06/30/14